RNAi for Therapeutics Market Revenue 2024 to 2034
RNAi for Therapeutics Market Revenue 2024 to 2034
The RNAi for Therapeutics Market will expand from USD 2.38 Bn in 2024 to USD 19.66 Bn by 2034, registering an impressive CAGR of 23.5%.
Report ID: 10297
|
Format: Databook
|
Published: August 2025
|
Delivery: Immediate
Download Sample
Customisation Request
Revenue,
USD USD 2.38 Bn
Forecast Year,
USD USD 19.66 Bn
CAGR, 2025 -
23.5%
Report Coverage
Worldwide
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
RNAi for Therapeutics Market Size Analysis
RNAi for Therapeutics Market Size By Modality 2024 to 2034 (USD )
| Modality | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| siRNA | 1.33 | 1.65 | 2.03 | 2.51 | 3.10 | 3.85 | 4.77 | 5.91 | 7.28 | 8.95 | 11.05 |
| shRNA | 0.38 | 0.47 | 0.58 | 0.71 | 0.88 | 1.07 | 1.32 | 1.62 | 2.00 | 2.50 | 3.06 |
| miRNA | 0.43 | 0.53 | 0.65 | 0.81 | 1.00 | 1.22 | 1.51 | 1.86 | 2.31 | 2.86 | 3.57 |
| Other RNAi | 0.24 | 0.29 | 0.36 | 0.45 | 0.56 | 0.69 | 0.85 | 1.04 | 1.29 | 1.60 | 1.98 |
RNAi for Therapeutics Market Size By Delivery 2024 to 2034 (USD )
| Delivery | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lipid Nanoparticles | 1.09 | 1.35 | 1.67 | 2.07 | 2.55 | 3.15 | 3.89 | 4.82 | 5.93 | 7.35 | 9.08 |
| GalNAc Conjugates | 0.76 | 0.94 | 1.16 | 1.43 | 1.77 | 2.18 | 2.69 | 3.33 | 4.12 | 5.07 | 6.28 |
| Viral/Other | 0.52 | 0.64 | 0.79 | 0.98 | 1.21 | 1.50 | 1.86 | 2.28 | 2.83 | 3.48 | 4.29 |
RNAi for Therapeutics Market Size By Indication 2024 to 2034 (USD )
| Indication | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare/Genetic | 0.67 | 0.82 | 1.01 | 1.25 | 1.55 | 1.92 | 2.37 | 2.92 | 3.61 | 4.47 | 5.53 |
| Liver Diseases | 0.62 | 0.76 | 0.94 | 1.15 | 1.42 | 1.76 | 2.18 | 2.69 | 3.34 | 4.13 | 5.06 |
| Oncology | 0.52 | 0.65 | 0.80 | 0.99 | 1.23 | 1.52 | 1.88 | 2.32 | 2.87 | 3.53 | 4.37 |
| Cardio-Metabolic | 0.33 | 0.41 | 0.51 | 0.63 | 0.78 | 0.96 | 1.18 | 1.45 | 1.80 | 2.22 | 2.75 |
| Others | 0.24 | 0.29 | 0.36 | 0.45 | 0.55 | 0.68 | 0.84 | 1.04 | 1.27 | 1.57 | 1.94 |
RNAi for Therapeutics Market Size By End-User 2024 to 2034 (USD )
| End-User | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals/Clinics | 0.71 | 0.87 | 1.08 | 1.34 | 1.65 | 2.04 | 2.52 | 3.10 | 3.85 | 4.75 | 5.90 |
| Pharma & Biotech | 1.28 | 1.59 | 1.97 | 2.42 | 2.99 | 3.70 | 4.58 | 5.67 | 6.98 | 8.63 | 10.62 |
| Research/Academic | 0.29 | 0.35 | 0.43 | 0.54 | 0.67 | 0.83 | 1.01 | 1.25 | 1.54 | 1.90 | 2.35 |
| Others | 0.10 | 0.12 | 0.15 | 0.18 | 0.22 | 0.27 | 0.34 | 0.41 | 0.51 | 0.63 | 0.78 |
RNAi for Therapeutics Market Size By Region 2024 to 2034 (USD )
| Region | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 1.05 | 1.29 | 1.60 | 1.99 | 2.46 | 3.06 | 3.77 | 4.63 | 5.70 | 7.02 | 8.67 |
| Europe | 0.71 | 0.88 | 1.08 | 1.33 | 1.64 | 2.01 | 2.49 | 3.07 | 3.80 | 4.69 | 5.82 |
| Asia Pacific | 0.52 | 0.65 | 0.80 | 0.99 | 1.22 | 1.50 | 1.86 | 2.32 | 2.87 | 3.57 | 4.39 |
| Latin America | 0.05 | 0.06 | 0.07 | 0.09 | 0.11 | 0.13 | 0.16 | 0.20 | 0.25 | 0.31 | 0.39 |
| Middle East & Africa | 0.05 | 0.06 | 0.07 | 0.09 | 0.11 | 0.13 | 0.16 | 0.20 | 0.25 | 0.32 | 0.39 |
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
